Two major pharmaceutical companies developing advanced-stage R&D on Alzheimer’s disease have just pulled the plug on their research. The reason why their approach to Alzheimer’s, Aducanumab, failed is because it didn’t account for a factor that is central
to R&D conducted by biotechnology Company ProMIS Neurosciences Inc.
(TSX:PMN, OTCQB:ARFXF, Forum).
Preclinical studies show the Company's lead antibody candidate, PMN310,
demonstrates a high degree of binding to toxic oligomers from Alzheimer's disease brains without binding to plaque or other non-toxic forms of the toxic oligomer form of
amyloid beta (Aβ).
Not only has an important competitor dropped out of the race to find an Alzheimer’s
treatment, the reason for failure suggests that ProMis is on the right track with its own
research.
Stockhouse is joined by Company President and CEO, Dr. Elliot Goldstein to learn
more about ProMIS’ research and potential to combat Alzheimer’s Disease.
Blockchain 101 Podcast - Eps 1 - Alex Tapscott
Podcast #63 Group Eleven Resources Corp.
Podcast #62 Zomedica Pharmaceuticals Corp.
Podcast #61 Orefinders Resources Inc.
Podcast #57 Midnight Sun Mining
HIKU/DOJA Interview
Podcast #60 First Majestic Silver Corp.
Podcast #59 IGC Inc
Podcast #58 CVR Medical Corp
Podcast #57 Universal mCloud Inc
Podcast #56 GoldMining Inc
Podcast #55 Greenfields Petroleum Corp
Podcast #54 Cobalt Power Group
Podcast #53 Nutritional High International
Podcast #52 Friday Night Inc
Podcast #51 Molori Energy
Podcast #50 North Arrow Minerals Inc.
Podcast #49 Global UAV
Frank Curzio interviews Amir Adnani
Podcast #48 Teranga Gold
Create your
podcast in
minutes
It is Free
The Commercial Edge: Unleash the Power of People
The emPOWERed Half Hour
U.S Property Podcast
Aligned Money Show
Dubai Property Podcast
The Ramsey Show
The Clark Howard Podcast